Seragon Pharmaceuticals Inc., a new San Diego company focused on breast cancer therapies, has raised $30 million in Series A financing.
The company was created by the founders of Aragon Pharmaceuticals Inc., a company that was sold this in August to Johnson & Johnson for about $1 billion. J&J acquired the company for its drug that treats prostate cancer.
The founders and several staff members from Aragon have transitioned over to Seragon, which now employs 22.
Investors in this financing round included venBio, Topspin Fund, Aisling Capital, OrbiMed Advisors and The Column Group.
— SDBJ Staff Report